Combination Chemotherapy in Treating Patients With Advanced Colorectal CancerStudy of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal MelanomaA Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of DarolutamideSBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck CarcinomaDurvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLCModifying Your Diet to Support Muscle During Cancer TreatmentVaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in SurgeryA Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular CarcinomaUnilateral Neck Radiotherapy in Head and Neck CancerPhase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung CancerQuantifying Lung Tumor Movement Under Deep Inspiration Breath HoldsCetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal CancerA Pilot Study to Evaluate the Feasibility of Combining Submandibular Salivary Gland Tx & IMRT Tomo to Reduce XerostomiaPhase II Trial of Erlotinib in Advanced Pancreatic CancerBortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaA Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaNutritional Status and Barriers to Dietary Intake in Head and Neck Cancer PatientsA Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsStudy Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast CancerMulticenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal CancerA Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast CancerSB939 in Treating Patients With Recurrent or Metastatic Prostate CancerA Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or LymphomaNivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic ProfileACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaPrevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the ProstateTrametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaStereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer PatientsA Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerInterleukin-21 in Treating Patients With Metastatic or Recurrent Malignant MelanomaSafety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and CachexiaA Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant MelanomaCT-Based Versus Conventional Simulation for Palliative Radiotherapy of Non-Small Cell Lung CancerThe UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical RadiotherapyMulti-Center Study of GSK2857916 in Combination With Pomalidomide and DexBrachytherapy in Treating Patients With Prostate CancerDNA Variations in the Gene in Young Patients With Wilms' TumorISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
P6153
Q30093177-68235F00-BA2E-4B54-9605-9F3B9C036D34Q43233378-5E28C37A-47A0-4D60-932B-3BC23345254DQ57314954-7E880BA9-3117-467B-B2A9-4D22229FD530Q57618427-E6B1C063-4030-49B2-B758-7A3CF2B5BBABQ67965496-20B5A989-C6C3-4FDE-BCC8-5B30BA3D2D4EQ82366827-31628519-70BC-47CD-AD38-F16FC97E1248Q88925677-4160359C-7C73-47F3-88D2-D5FC5BA83FFAQ88925677-7BD52271-6BD0-46B5-AB17-3B8D133E1981Q88925677-AEA47CBF-4152-441B-B9A5-D3FB800931F3
P108
Q58407403-B5B0A0F5-718C-4332-B12B-20981A42CE0CQ58407581-90796BF9-9B6E-471F-8224-4B9F41152E45Q58407655-89805726-DEBB-4469-8B42-A62AF911F58EQ58407896-09380E35-9C02-42AE-BB6C-E2C4DD542099Q58846155-3B6D521C-E823-4681-B7BF-6FF9C74F66FEQ58846939-54794A3F-1A25-4952-AE46-8ED33FC82621Q58848851-F7FC6FC3-104C-4ABE-A22C-7DE1629629B8Q61729699-DB5AF486-E6A4-4E5C-AA6E-D267C5A6F19EQ61862160-3865FF85-B96F-4F44-A0B9-B2409087508EQ61902512-B34FC528-6BC9-4FB9-BDF2-F59BB5C917F9Q61914628-BF5C374B-7EFD-406F-BA3D-7663D92A5BF3Q61914630-E1C88FA8-6E04-46B5-A4E5-79E84353124DQ61914924-631E9CC4-A225-4494-B2B9-1248E9B06C7BQ61917412-A5643B0D-2B65-4AF6-A2CE-75C4AB05E345Q61917427-A635D34F-4455-4B69-8AD9-A6466448E119Q61921297-E9F2AA95-CC14-4E12-9B43-31D67848FC03Q61922099-B1CD48DC-8AEE-4D4E-B364-9C507E14DA42Q61932390-262E1CF2-D949-4321-B229-F2E67C4DE17CQ61932780-7D225938-2960-4EF2-A797-30B46B176E6BQ61932852-5B69C1D6-AA91-4758-9C51-C1EF103F0B23Q61934934-1E38A979-08E8-47A6-BD23-84699F1FD4E9Q61936011-BB1B17AD-CFF2-439B-AE14-A66BF78802D4Q61938250-F17A62FF-C1B2-4C97-96AD-44D8BCD316AAQ61939334-E08D99A6-C52F-49D1-A627-0B7C969BACFAQ61955488-F91F4820-022A-4E73-95FA-ECC81CD86C1AQ61966605-1DC034AE-B9B9-458D-A9B4-A30329B9055CQ61969493-9D2F1C10-BD75-4094-AF0E-B3AB5168F289Q61969586-C9EDB186-9B3F-42C3-89CB-836CDA01E613Q61970161-05AA672E-8F64-4599-8EE7-EFA1277EEEE9Q61975474-1E8B6BAC-4DA9-46A4-938D-0069DF5394D9Q61975530-FF1BAE5F-FFE0-4266-A6E5-102443D40B8BQ61978911-709B756D-86A6-4E44-8AE1-3EFDDA529DDFQ61980939-8AFE21C5-F33D-4E13-8C8B-9DA76983C658Q61981180-D2C7D2E7-4A46-4B3A-AA0A-7B3692CC6C9BQ61981351-47E71636-5412-4AE9-BB12-FA3655A0CEECQ62035375-FCE4F107-74AA-4661-840F-E64866CD41BCQ62040994-149A3DE7-393C-44FB-BA90-AA1DD85BD421Q62109997-901167CB-46F3-4C48-92C1-4BBA995FBD66Q62110114-AA4036C9-C5F4-4DD2-93E7-625F34E57B44Q62110128-55D1DA77-A97E-43C1-8FAE-F93DAC040522
P6153
description
Comprehensive cancer centre for northern Alberta
@en
Krankenhaus
@de
griya sakit
@jv
hospital de Canadá
@ast
hôpital
@fr
rumah sakik
@min
rumah sakit di Kanada
@id
rumoh sakét
@ace
ziekenhuis in Alberta, Canada
@nl
בית חולים בקנדה
@he
name
Cross Cancer Institute
@en
type
label
Cross Cancer Institute
@en
prefLabel
Cross Cancer Institute
@en
P214
P244
P6366
P131
P17
P213
0000 0000 8927 6097
P214
P244
P3500
P571
1968-01-01T00:00:00Z
P625
Point (-113.531 53.5178)
P6366
1307383912
P7859
lccn-n85090088